Optomed Oyj Class A · OMXHEX:OPTOMED
Optomed Oyj Class A — Q4 2025 Earnings Presentation
16 slides from Optomed Oyj Class A's earnings presentation, Feb 10, 2026
Slide 1: Optomed Q4 2025
Optomed Q4 2025 10th February 2026 Juho Himberg, CEO Sakari Knuutti, CFO
Slide 2: Highlights Q4
Highlights Q4 1. 2. 3. The highest revenue The US market Share issue carried of the year achieved continued to out during the quarter: during the quarter perform very well approximately MEUR 6 gross proceeds
Slide 3: Q4-2025 Key Figures
Q4-2025 Key Figures REVENUE BELOW THE LAST YEAR DUE TO A 1.5 MEUR ORDER RECEIVED IN Q4-2025 Q4/2025 Q4/2024 Change Revenue 4,812 5,099 -5.6% Gross profit 2,961 3,321 -10.9% Gross margin 61.5% 65.1% -360bps EBITDA -1,333 -812 -64.2% EBITDA margin -27.7% -15.9% -11.8pp Net profit / loss -1,885 -989 -9
Slide 4: FY2025 Key Figures
FY2025 Key Figures CURRENCY-ADJUSTED REVENUE GROWTH WAS 15.4 PERCENT IN 2025 Q1-Q4/2025 Q1-Q4/2024 Change Revenue 17,096 15,040 13.7% Gross profit 10,878 9,676 12.4% Gross margin 63.6% 64.3% -70bps EBITDA -3,526 -3,458 -2.0% EBITDA margin -20.6% -23.0% +2.4pp Net profit / loss -6,640 -5,450 -21.8% E
Slide 5: Segment highlights
Segment highlights OPT@MED
Slide 6: Devices Segment Q4-2025
Devices Segment Q4-2025 DEVICES SEGMENT ACHIEVED THE HIGHEST REVENUE OF THE YEAR BUT FACED VERY STRONG COMPARISONS Q4/2025 Q4/2024 Change Currency-adjusted revenue 1. decreased 3.3% against strong comparisons Revenue 2,380 2,551 -6.7% Both capex sales and Aurora AEYE Gross profit 1,305 1,476 -11.6%
Slide 7: Software Segment Q4-2025
Software Segment Q4-2025 SOFTWARE EBITDA AFFECTED BY ONE-TIMERS Q4/2025 Q4/2024 Change Healthcare business grew while 1. non-healthcare consulting revenue continued its decline Revenue 2,432 2,549 -4.6% Gross profit 1,656 1,845 -10.2% 2. EBITDA affected by one-timers Gross margin 68.1% 72.4% -430bps
Slide 8: Strategic Progress
Strategic Progress CONTINOUS PROGRESS Large Aurora AEYE recurring revenue 1. base achieved during the year: continuous growth every quarter 2. First full quarter of Optomed Lumo sales The collaboration with a global top-10 3. pharma company progressed with commercial agreement negotiations China: jo
Slide 9: Cash Flow Q4-2025
Cash Flow Q4-2025 STRONG CASH POSITION Q4 2025 Q4 2024 Loss for the financial year -1,885 -989 Cash flows before change -1,129 -349 in net working capital • Share issue carried out during Change in net working capital 1,029 690 the quarter: approximately Cash flows before finance items -101 341 MEUR
Slide 10: Outlook 2026
Outlook 2026 OPTOMED EXPECTS ITS FULL YEAR 2026 REVENUE TO GROW COMPARED TO 2025 Key items supporting our growth: Areas of uncertainty and pressure on growth: • Large Aurora AEYE recurring revenue base in • Software segment growth facing difficult the US at the start of the year: growth every domest
Slide 11: FY 2025 in summary
FY 2025 in summary • Devices grew almost 50% at currency adjusted basis and USA was over 50% of the revenue • Software segment declined slightly but the healthcare business grew • Large Aurora AEYE recurring revenue base achieved, and many mid sized capex orders received in the US • Finished with a
Slide 12: Appendix
Appendix OPT@MED
Slide 13: Devices Segment Q1-Q4/2025
Devices Segment Q1-Q4/2025 Q1-Q4/2025 Q1-Q4/2024 Change 1. Revenue grew 43.1 % Revenue 7,620 5,326 43.1% Gross profit 4,255 2,778 53.2% 2. EBITDA increased 73.8% Gross margin 55.8% 52.2% +370bps EBITDA -438 -1,673 73.8% EBITDA margin -5.7% -31.4% +25.7pp
Slide 14: Software Segment Q1-Q4/2025
Software Segment Q1-Q4/2025 Q1-Q4/2025 Q1-Q4/2024 Change 1. Revenue decreased 2.5% Revenue 9,475 9,714 -2.5% Gross profit 6,623 6,889 -3.9% 2. EBITDA decreased 32.5% Gross margin 69.9% 70.9% -10bps EBITDA 1,281 1,897 -32.5% EBITDA margin 13.5% 19.5% -6.0pp
Slide 15: Cash Flow Q1-Q4/2025
Cash Flow Q1-Q4/2025 Q1-Q3 2025 Q1-Q3 2024 • Cash flows before change Loss for the financial year -6,640 -5,450 in net working capital Cash flows before change EUR -3.2 million in net working capital -3,158 -2,764 • Cash position at EUR 9.9 Change in net working capital 727 1,254 million Cash flows
Slide 16: Balance Sheet
Balance Sheet 31 December 2025 31 December 2024 • Equity ratio of 75.1 (74.4) ASSETS Goodwill 4,256 4,256 percent Development costs 8,739 8,288 Other intangible assets 1,093 1,421 • Total borrowings of EUR Total intangible assets 14,089 13,965 1.4 (2.3) million Total tangible assets 894 652 Total no